Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports ...
The management of Leishmania donova ni (LD), responsible for fatal visceral leishmaniasis (VL), faces increasing challenges due to rising drug-unresponsiveness, leading to increasing treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback